Fundamental Analysis of NOVOCURE LTD(NASDAQ:NVCR) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NVCR. NVCR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NVCR have multiple concerns. While showing a medium growth rate, NVCR is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

NVCR had negative earnings in the past year.

In the past year NVCR has reported a negative cash flow from operations.

NVCR had negative earnings in 4 of the past 5 years.

NVCR had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

NVCR has a Return On Assets of -12.26%. This is comparable to the rest of the industry: NVCR outperforms 57.22% of its industry peers.

NVCR has a Return On Equity (-41.52%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-12.26%
ROE	-41.52%
ROIC	N/A

ROA(3y)-10.32%

ROA(5y)-6.11%

ROE(3y)-30.77%

ROE(5y)-18.29%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of NVCR (76.42%) is better than 88.77% of its industry peers.

In the last couple of years the Gross Margin of NVCR has grown nicely.

NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	76.42%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.57%

GM growth 5Y2.01%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NVCR has been increased compared to 1 year ago.

Compared to 5 years ago, NVCR has more shares outstanding

Compared to 1 year ago, NVCR has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.46, we must say that NVCR is in the distress zone and has some risk of bankruptcy.

NVCR has a Altman-Z score of 1.46. This is comparable to the rest of the industry: NVCR outperforms 52.41% of its industry peers.

A Debt/Equity ratio of 1.81 is on the high side and indicates that NVCR has dependencies on debt financing.

NVCR's Debt to Equity ratio of 1.81 is on the low side compared to the rest of the industry. NVCR is outperformed by 84.49% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.81
Debt/FCF	N/A
Altman-Z	1.46

ROIC/WACCN/A

WACC7.96%

2.3 Liquidity

A Current Ratio of 1.49 indicates that NVCR should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.49, NVCR is doing worse than 78.61% of the companies in the same industry.

A Quick Ratio of 1.44 indicates that NVCR should not have too much problems paying its short term obligations.

The Quick ratio of NVCR (1.44) is worse than 62.57% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.49
Quick Ratio	1.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.73% over the past year.

Looking at the last year, NVCR shows a quite strong growth in Revenue. The Revenue has grown by 14.63% in the last year.

Measured over the past years, NVCR shows a quite strong growth in Revenue. The Revenue has been growing by 15.47% on average per year.

EPS 1Y (TTM)24.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.13%

Revenue 1Y (TTM)14.63%

Revenue growth 3Y1%

Revenue growth 5Y15.47%

Sales Q2Q%21.81%

3.2 Future

Based on estimates for the next years, NVCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.16% on average per year.

Based on estimates for the next years, NVCR will show a quite strong growth in Revenue. The Revenue will grow by 13.26% on average per year.

EPS Next Y32.4%

EPS Next 2Y10.24%

EPS Next 3Y8.06%

EPS Next 5Y9.16%

Revenue Next Year17.36%

Revenue Next 2Y11.18%

Revenue Next 3Y10.78%

Revenue Next 5Y13.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.24%

EPS Next 3Y8.06%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NVCR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVOCURE LTD

NASDAQ:NVCR (12/4/2024, 1:45:50 PM)

28.9001

-1.61 (-5.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.13B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.26%
ROE	-41.52%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	76.42%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	1.81
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.49
Quick Ratio	1.44
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)24.73%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y32.4%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)14.63%

Revenue growth 3Y1%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NOVOCURE LTD (NVCR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens